Lectin-Modified Magnetic Nano-PLGA for Photodynamic Therapy In Vivo
Lectin-modified nano-PLGA nanoparticles loaded with photodynamic therapy sensitizer (IR775) and magnetite (mPLGA/IR775) were shown to be effective theranostic agents, realizing effective magnetically assisted targeted delivery, tumor bioimaging, and treatment under external light irradiation. The in vitro and in vivo functionality of these nanoparticles were thoroughly tested, and 100% inhibition of allograft solid tumor growth was shown, thus confirming the great potential of the developed nanoformulation for bioimaging and photodynamic therapy. The results are published in Pharmaceutics. Learn more
- Lectin-Modified Magnetic Nano-PLGA for Photodynamic Therapy In Vivo
The extreme aggressiveness and lethality of many cancer types appeal to the problem of the development of new-generation treatment strategies based on smart materials. The targeted delivery of nanoparticles to specific cancer cell receptors is believed to be such a strategy; however, there are no targeted nano-drugs that have successfully completed clinical trials to date. To meet the challenge, the team of the Laboratory of Molecular Immunology of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, the Laboratory for Biochemical Research of Carcinogenesis of the Moscow Institute of Physics and Technology, and the Department of Nanobiomedicine of the Sirius University, have developed an alternative method of oncotherapy.
- RALF peptides modulate immune response in the moss Physcomitrium patens
Plants utilize small secreted peptides as important mediators of many processes, from growth and development to response to stress conditions. One of such regulators is the conservative 5 kDa cysteine-rich RALF (Rapid Alkalinization Factor) peptide family, which is widely present in terrestrial plants. RAPID ALKALINIZATION FACTOR (RALFs) are peptides that regulate multiple physiological processes in plants. This peptide family has considerably expanded during land plant evolution, but the role of ancient RALFs in modulating stress responses is unknown
- Antibody fragment-drug conjugates selectively eliminate GD2-expressing tumor cells
Employing antibody fragments instead of full-length antibodies in antibody-drug conjugates can facilitate accumulation of the therapeutics in the tumor and reduce their side effects. Scientists from the Laboratory of molecular immunology together with colleagues from the Laboratory of cell interactions, the Laboratory of molecular diagnostics at IBCh RAS, and other Russian Institutes have for the first time developed GD2-specific antibody fragment-drug conjugates. Minibody and scFv fragment conjugates with the tubulin-inhibiting drugs MMAE and MMAF manifested strong cytotoxic and cytostatic effects in GD2-positive neuroblastoma and melanoma cell lines.